Advertisement
Australia markets close in 4 hours 52 minutes
  • ALL ORDS

    8,255.70
    -6.70 (-0.08%)
     
  • ASX 200

    8,008.90
    -8.70 (-0.11%)
     
  • AUD/USD

    0.6748
    -0.0017 (-0.25%)
     
  • OIL

    81.79
    -0.12 (-0.15%)
     
  • GOLD

    2,428.80
    -0.10 (-0.00%)
     
  • Bitcoin AUD

    95,988.15
    +4,411.61 (+4.82%)
     
  • CMC Crypto 200

    1,344.44
    +75.49 (+5.94%)
     
  • AUD/EUR

    0.6194
    -0.0006 (-0.10%)
     
  • AUD/NZD

    1.1125
    +0.0002 (+0.02%)
     
  • NZX 50

    12,116.19
    -6.95 (-0.06%)
     
  • NASDAQ

    20,386.88
    +55.38 (+0.27%)
     
  • FTSE

    8,182.96
    -69.95 (-0.85%)
     
  • Dow Jones

    40,211.72
    +210.82 (+0.53%)
     
  • DAX

    18,590.89
    -157.31 (-0.84%)
     
  • Hang Seng

    18,015.94
    0.00 (0.00%)
     
  • NIKKEI 225

    41,417.86
    +227.18 (+0.55%)
     

Melodiol Global Health Full Year 2023 Earnings: AU$0.019 loss per share (vs AU$0.45 loss in FY 2022)

Melodiol Global Health (ASX:ME1) Full Year 2023 Results

Key Financial Results

  • Revenue: AU$19.7m (up 121% from FY 2022).

  • Net loss: AU$35.5m (loss widened by 8.4% from FY 2022).

  • AU$0.019 loss per share.

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Melodiol Global Health shares are down 30% from a week ago.

Risk Analysis

Be aware that Melodiol Global Health is showing 5 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.